FDA Approves Recombinant Flu Vaccine

The agency's approval of the first seasonal flu vaccine made of recombinant proteins rather than inactivated or weakened virus comes as emergency rooms are clogged with victims of an early and severe flu season















Share on Tumblr

flu shot, recombinant flu vaccine, boy getting flu shot

Image: CDC/Judy Schmidt

From Nature.

The US Food and Drug Administration (FDA) has approved the first seasonal flu vaccine comprised of recombinant proteins, rather than inactivated or weakened virus.

The 16 January approval of Flublok, developed by Protein Sciences Corporation in Meriden, Connecticut, arrives as US emergency rooms are clogged with victims of an early and severe flu season. Thirty states are reporting high levels of flu-like illness this season, and New York state and the city of Boston have declared public health emergencies. Vaccine supplies are dwindling.

Flublok is one of a new wave of flu vaccines intended to make production more nimble. The three influenza hemagglutinin proteins comprising Flublok are made in insect cells rather than in chicken eggs, the classical incubator for seasonal flu vaccine. It is the second egg-free vaccine to be approved by the FDA. In November, the agency approved Flucelvax, made by the Swiss pharmaceutical firm Novartis.

But it has been a long road to approval for Protein Sciences. FDA advisors narrowly rejected the vaccine in 2009, arguing that there was insufficient evidence that the vaccine was safe. Development of Flublok and a related pandemic flu vaccine called Panblok was subsidized by a Biomedical Advanced Research and Development Authority (BARDA) contract awarded in 2009, but then threatened when Emergent BioSolutions of Rockville, Maryland and two other creditors sued Protein Sciences for failing to repay over $11 million in loans. The lawsuit was settled in 2010.

Flublok will be out on the market in full force in time for the 2013-2014 flu season, and limited supplies will be available to help out during the current season.

This article is reproduced with permission from the Nature News Blog. The article was first published on January 17, 2013.



1 Comments

Add Comment
View
  1. 1. comefullcircle 01:48 AM 1/27/13

    You couldn't pay me enough money to be the recipient of any vaccination these days. The Polio vaccination campaign of the 1950's and beyond revealed how the government reacted, once it was learned that those vaccinations were contaminated with a plethora of viruses - the one called "SV-40" being the one of paramount concern (and it was numbered at number 40 because it was the fortieth one they discovered in the vaccinations.) After it was discovered that the vaccinations sitting on shelves all over the country were contaminated, they were not recalled immediately like one would deem appropriate. Instead, because of the money that had been invested in the existing vaccines, they continued to dispense those contaminated vaccines into the 1960's. Think I'm crazy, or making this up; or imagining this? Think again, and do your own research: read a book called "Dr. Mary's Monkey" and educate yourself.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital

Latest from SA Blog Network

  SA Digital

Science Jobs of the Week

Email this Article

FDA Approves Recombinant Flu Vaccine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X